

Cell type-specific enhancer element associated with a mouse MHC gene, E_{β}

Stephen D. Gillies, Virginia Folsom & Susumu Tonegawa

Center for Cancer Research and Department of Biology,
 Massachusetts Institute of Technology, Cambridge,
 Massachusetts 02139, USA

Class II molecules of the major histocompatibility complex (MHC) are heterodimeric glycoproteins expressed on the surface of antigen-presenting B lymphocytes and macrophages¹. The genes encoding the α - and β -chains of the class II heterodimers, $A_{\alpha}A_{\beta}$ and $E_{\alpha}E_{\beta}$, have recently been characterized at the molecular level²⁻⁵, and certain cloned genes were shown to be functionally expressed after introduction into cells by DNA-mediated gene transfer^{6,7}. One study⁷ found that a transfected E_{β} gene was expressed in a macrophage cell only after treatment of cells with γ -interferon. DNA sequences associated with transfected Class II MHC genes may therefore have a regulatory role in their cell type-specific expression. We report here the identification of a cell type-specific transcriptional enhancer element associated with the mouse E_{β} gene.

We⁸ and others^{9,10} have recently shown that the tissue-specific expression of immunoglobulin heavy-chain genes is regulated by an immunoglobulin heavy-chain gene-associated enhancer element located between J_H and C_{μ} . This enhancer functions in cells which normally express heavy-chain genes but not in cells derived from other tissues, for example, fibroblasts. The possibility that an enhancer element might be associated with the mouse E_{β} gene was tested by subcloning restriction fragments of the gene and its flanking regions into the *EcoRI* site of plasmid pSER and testing the ability of the recombinant plasmids to transform the B lymphoma line, A20-2J (ref. 11) to the *gpt*⁺ phenotype (growth in the presence of mycophenolic acid). This plasmid was derived from plasmid pSV2*gpt* (ref. 12) by removing the simian virus 40 (SV40) enhancer sequence³. In the absence of any E_{β} gene fragments, plasmid pSER transformed A20-2J cells to *gpt*⁺ at a frequency of $<5 \times 10^{-6}$ while the transformation frequency obtained with the parental plasmid, pSV2*gpt* (containing the SV40 enhancer) was $\sim 10^{-4}$. We conclude from these data and similar results with the myeloma cell line, J558L (ref. 8), that plasmid pSER is dependent on the

addition of enhancer sequences for efficient transformation.

Only one region out of 28 kilobases (kb) of E_{β} coding and flanking sequences (Fig. 1) was found to be positive in this assay—a 4.1-kb *HindIII*-*EcoRI* fragment containing the first exon and approximately 2.7 kb of upstream sequence (see Table 1a). As the site of insertion of this fragment in plasmid pSER is some distance (2.5 kb) away from the SV40 promoter, and the 4.1-kb fragment worked equally well in both orientations (see below), we tentatively conclude that an enhancer element is located in this region of the E_{β} gene.

The subfragments shown in Fig. 1 were then tested for their ability to substitute for the SV40 enhancer. These fragments included three which extend from the 5' end of the 4.1-kb fragment (*HindIII* site) but differ at their 3' ends. As seen in Table 1b, fragments extending either to the *BstXI* site near the E_{β} gene promoter (HX fragment) or to the *BamHI* site at about -600 base pairs (bp) (HB fragment) were shown to contain full enhancing activity. The *BstXI* to *EcoRI* fragment (XR), containing the first E_{β} gene exon and a portion of the first intron, had no detectable activity. We have previously reported that two short sequences present upstream of the E_{β} gene promoter are conserved in the corresponding regions of the murine E_{α} and DR_{α} genes⁵ (see Fig. 3). As the HB and HX fragments worked equally well in the enhancer assay, even though these sequences were not contained in the HB fragment, we conclude that these elements are not necessary for enhancing activity.

Subfragments of the 2.0-kb HB fragment were negative in the pSER assay (Table 1). These include the fragments produced by cleavage with *PvuII* (HP and PB) and a fragment spanning the *PvuII* site (AA). Thus it seems that the sequences required for enhancer activity are scattered over the 2.0-kb HB fragment.

Next we tested the recombinant plasmids that gave positive results in A20-2J cells for enhancing activity in other murine cell types (Table 1). No activity was detected when the 4.1-kb or HB fragment recombinants were used to transfect fibroblasts (L cells), indicating that this enhancing activity is tissue-specific. These same plasmid constructs also gave negative results in a myeloma J558L, a tumour of plasma cells which are terminally differentiated B-lineage cells not expressing class II antigens. In contrast, the pSER recombinant containing the immunoglobulin heavy-chain enhancer⁸ was positive in both the B-lymphoma (A20-2J) and myeloma lines. We conclude that the cell type-specific expression of the E_{β} gene is due, at least in part, to the functionality of its associated enhancer element.




Fig. 1 Restriction map of the mouse E_{β} gene and flanking regions. The locations of the coding exons (solid boxes) are from ref. 5. The direction of transcription is from left to right. The 4.1-kb *HindIII* to *EcoRI* site is enlarged and the sequencing strategy of the 5' flanking region is indicated with arrows. Subfragments used to test enhancing activity (Table 1) are shown above and are abbreviated by letters which correspond to their 5' and 3' restriction sites.




Fig. 2 Enhancement of $\gamma 2b$ heavy-chain mRNA transcription in J558L myeloma and A20-2J lymphoma cells. *a*, Diagram of plasmid pSV- $\gamma 2b\Delta X_{2/4}$ (ref. 8) and the site of insertion of the 2.0-kb HB fragment from the 5' flanking region of the E_{β} gene. This plasmid contains a functionally rearranged $\gamma 2b$ heavy-chain immunoglobulin gene but the heavy-chain enhancer has been removed (see Gillies *et al.*,⁸ for details). The HB fragment was inserted in both orientations ~ 1.4 kb upstream of the $\gamma 2b$ promoter. *b*, Diagram of the S_1 nuclease protection assay used to measure $\gamma 2b$ mRNA levels. A single-stranded *Hind*III to *Bst*NI fragment (140 nucleotides, nt) was hybridized to total cell RNA (20 μ g) from transfected and control cells. The 40-nucleotide major protected fragment is indicated. *c*, Electrophoretic analysis of fragments protected by RNA from cells transfected with plasmid pSV- $\gamma 2b\Delta X_{2/4}$ (lanes 1 and 5) and recombinants containing the heavy-chain enhancer (lanes 2 and 6) or the E_{β} HB fragment in the normal (lanes 3 and 7) or reversed orientations (lanes 4 and 8). An arrow indicates the 40-nucleotide major protected fragment.

In order to prove more directly that the E_{β} gene carries an associated enhancer element, we inserted the HB fragment into plasmid pSV- $\gamma 2b\Delta X_{2/4}$ and analysed the levels of $\gamma 2b$ mRNA in stably transformed A20-2J or J558L cells (pools of several independent colonies.) Plasmid pSV- $\gamma 2b\Delta X_{2/4}$ contains the coding sequences and transcriptional promoter for the $\gamma 2b$ immunoglobulin heavy chain but lacks the heavy-chain enhancer⁸. High-level expression of the $\gamma 2b$ gene in cells transformed with pSV- $\gamma 2b\Delta X_{2/4}$ was shown previously to be dependent on the addition of a functional enhancer^{8,13}.

The levels of $\gamma 2b$ mRNA, determined by S_1 nuclease protection, were compared in A20-2J and J558L cells transfected with plasmid pSV- $\gamma 2b\Delta X_{2/4}$ containing either no inserted DNA, fragment $X_{2/3}$ (heavy-chain enhancer), or the E_{β} HB fragment in either orientation (Fig. 2). The results show that J558L cells transfected with the construct containing the heavy-chain enhancer contained high levels of $\gamma 2b$ mRNA (lane 2 of Fig. 2c), confirming the results of our previous report⁸. In contrast, no

$\gamma 2b$ mRNA could be detected in J558L cells transfected with the constructs containing the E_{β} HB fragment in either orientation (lanes 3 and 4), even with much longer exposures of the autoradiogram (not shown). A lower level of $\gamma 2b$ mRNA (relative to J558L cells) was detected in A20-2J cells transfected with the plasmid construct containing the heavy-chain enhancer fragment (lane 6). In contrast to the results with J558L cells, A20-2J cells transfected with the E_{β} HB fragment constructs contained levels of $\gamma 2b$ mRNA that were comparable to that seen in the same host cell (A20-2J) with the heavy-chain enhancer (lanes 7 and 8).

Transfected cell lines were analysed further by Southern blotting to determine the plasmid copy numbers (data not shown). Except for the J558L line, obtained by transfection with the heavy-chain enhancer-containing plasmid (one or two copies per cell), all of the lines of both A20-2J and J558L contained a high copy number (about 40 copies per cell). This dramatic effect of the heavy-chain enhancer on the plasmid copy number in J558L transfectants, obtained by gpt selection, was described previously⁸. When the level of $\gamma 2b$ mRNA (determined by S_1 nuclease protection; Fig. 2) is normalized to the number of gene

Table 1 Relative transformation frequencies of pSV2gpt and derivative plasmids

Plasmid	Transfected cells		
	A20-2J	J558L	L
<i>a</i>			
pSV2gpt	1.0		
pSER	<0.1		
pSER-13+pSER-13 R	0.55		
pSER-0.7+pSER-0.7 R	<0.1		
pSER-1.9+pSER-1.9 R	<0.1		
pSER-12+pSER-12 R	<0.1		
pSER-8.6+pSER-8.6 R	0.05		
pSER-4.1+pSER-4.1 R	1.1		
<i>b</i>			
pSV2gpt	1.0	1.0	1.0
pSER	<0.05	0.02	0.05
pSER- $X_{2/3}$ (heavy chain)	1.9	1.5	0.05
pSER-4.1 R	1.6	<0.02	0.04
pSER-4.1	1.6		
pSER-HX R	1.9		
pSER-HX	1.9		
pSER-BX R	0.17		
pSER-BP R	<0.05		
pSER-HB R	2.0	<0.02	0.05
pSER-HB	2.0		
pSER-PB R	<0.05		
pSER-HP R	<0.05		
pSER-AA R	<0.05		
pSER-XR R	<0.05		

Cells were transfected by protoplast fusion as described⁸ and plated at 2×10^3 cells per well (A20-2J), 10^4 cells per well (J558L) or 10^4 and 10^5 cells per 100 mm dish (L cells). Selective medium contained mycophenolic acid at $1 \mu\text{g ml}^{-1}$ (A20-2J), $6 \mu\text{g ml}^{-1}$ (J558L) or $25 \mu\text{g ml}^{-1}$ (L cells). The transformation frequencies were normalized to a value of 1.0 which was assigned to the frequency obtained with plasmid pSV2gpt (10^{-4} for A20-2J, 4×10^{-4} for J558L and 2×10^{-3} for L cells). *a*, Four *Eco*RI fragments (13, 0.7, 1.9 and 12 kb long) covering ~ 28 kb of the E_{β} gene and its flanking regions (see Fig. 1) were cloned in both orientations into the *Eco*RI site of plasmid pSER. Bacterial cultures containing plasmids with the same fragment in both orientations were mixed before protoplast preparation. The positive 13-kb *Eco*RI fragment was subdivided into an 8.6-kb *Hind*III fragment and a 4.1-kb *Hind*III-*Eco*RI fragment. These fragments were cloned by blunt-end ligation into the *Eco*RI site of plasmid pSER and tested for transformation efficiency against A20-2J. *b*, The 4.1-kb *Hind*III-*Eco*RI fragment was further subdivided as described in the text. Each plasmid was tested at least three times using constructs containing the test DNA fragment in both orientations. For most fragments, only the reverse orientation with respect to gpt transcription is shown. Plasmid nomenclature: see Fig. 1 for the restriction fragments inserted into the *Eco*RI site of plasmid pSER. The letter R refers to the reverse orientation used for the transformation data shown.

the direction opposite that of E_{β} transcription. Three 'core-like' sequences, each containing a C residue between the third and fourth G residues of the core consensus sequence, are located between nucleotides 551 and 767. These sequences are spaced approximately 100 bp apart and each successive repeat contains an additional A or T between the third and fourth G residue than the one before it. A fourth 'core-like' sequence containing five A or T residues is located around nucleotide 1,100. All four 'core-like' sequences are contained within the *HindIII*-*PvuII* (HP) and *AvaII*-*AvaII* (AA) fragments which by themselves have no enhancer activity (Table 1).

The most striking feature of the sequence in this region is the dinucleotide repeats beginning with 24 TC repeats near the *HindIII* site. This is followed by a track of alternating purine-pyrimidines which extends for approximately 170 bp with only five single base pair interruptions. Shorter stretches are also found around nucleotides 250 and 800. Such sequences are known to have the potential of forming left-handed Z-DNA¹⁵, however this property is not by itself sufficient for the enhancing activity of the E_{β} enhancer as these sequences are located within the inactive HP fragment.

There are two additional tracks of purine-pyrimidine asymmetry—a GA repeat between nucleotides 1,001 and 1,054 and a TC repeat between nucleotides 1,411 and 1,450. It is not yet known whether such sequences have a role in E_{β} enhancer function. It should be noted, however, that the (TC)₂₄-(GA)₂₇-(TC)₂₀ tracts are all contained in the HB fragment (the smallest fragment with full enhancing activity) whereas the inactive HP, PB and AA fragments contain only one or two. Clearly, the individual contributions of the elements described above as well as those involved in the strict cell-type specificity of this enhancer will require much more refined analyses.

The results presented above provide another example of a cell type-specific cellular enhancer element which is likely to play an important part in the regulated expression of the associated gene. It will be interesting to determine to what extent the expression of other eukaryotic genes is controlled by enhancers or similar *cis*-acting elements such as the upstream activation sequences (UASs)¹⁶ of yeast and the 'modulator' sequences of the sea urchin histone¹⁷, human insulin and chymotrypsin genes¹⁸.

We thank Ms Lena Angman for technical help and Ms Eleanor Basel for secretarial assistance. V.F. is supported by a fellowship from the Cancer Research Institute. This work was supported by grants AI-17879 (S.T.) and CA-14051 (a core grant to S. Luria) from the NIH.

Received 1 May; accepted 14 June 1984.

1. Møller, G. *Immun. Rev.* **38**, 1-162 (1978).
2. Steinmetz, M., et al. *Nature* **300**, 35-42 (1982).
3. Hyldig-Nielsen, J. J. et al. *Nucleic Acids Res.* **11**, 5055-5071 (1983).
4. Mathis, D. J., Benoist, C. O., Williams, V. E. II, Kanter, M. R. & McDevitt, H. O. *Cell* **32**, 745-754 (1983).
5. Saito, H., Maki, R. A., Clayton, L. K. & Tonegawa, S. *Proc. natn. Acad. Sci. U.S.A.* **80**, 5520-5524 (1983).
6. Germain, R. N., Norcross, M. A. & Margulies, D. H. *Nature* **306**, 190-194 (1983).
7. Folsom, V. et al. *Proc. natn. Acad. Sci. U.S.A.* **81**, 2045-2049 (1984).
8. Gillies, S. D., Morrison, S. L., Oi, V. T. & Tonegawa, S. *Cell* **33**, 717-728 (1983).
9. Banerji, J., Olson, L. & Schaffner, W. *Cell* **33**, 729-740 (1983).
10. Neuberger, M. S. *EMBO J.* **2**, 1373-1378 (1983).
11. Kappler, J., White, J., Wegmann, D., Mustain, E. & Marrack, P. *Proc. natn. Acad. Sci. U.S.A.* **79**, 3604-3607 (1982).
12. Mulligan, R. C. & Berg, P. *Science* **209**, 1422-1427 (1980).
13. Hayday, A. C. et al. *Nature* **307**, 334-340 (1984).
14. Weiher, H., König, M. & Gruss, P. *Science* **219**, 626-631 (1983).
15. Wang, A. H. et al. *Nature* **282**, 680-686 (1979).
16. Guarente, L. & Mason, T. *Cell* **32**, 1279-1286 (1983).
17. Grosschedl, R. & Birnstiel, M. L. *Proc. natn. Acad. Sci. U.S.A.* **77**, 7102-7106 (1980).
18. Walker, M. D., Edlund, T., Boulet, A. M. & Rutter, W. J. *Nature* **306**, 557-561 (1983).
19. Maxam, A. M. & Gilbert, W. *Meth. Enzym.* **65**, 499-560 (1980).